Granulosa cell tumors are rare ovarian cancers with unique biology and treatment vulnerabilities compared to more common types of ovarian cancer. Current approaches to the treatment of recurrent or metastatic granulosa cell tumors include surgery to remove the tumor combined with either chemotherapy or hormone therapy. The principal investigator Dr. Tyler Hillman has a laboratory and clinical practice dedicated to making discoveries that improve the lives of patients affected by recurrent granulosa cell tumors.
Despite these ongoing efforts, there remain several significant barriers to curing this disease:
- Identification of new treatment options
- Optimizing how doctors use current treatment options based on patient-specific clinical and molecular data
- Improving our understanding of the causes and risk factors for granulosa cell tumors
To address these unmet needs, our team established a global granulosa cell tumor registry incorporating clinical and tumor molecular data. This registry will be tightly integrated with laboratory studies in order to accelerate innovation and catalyze collaboration between granulosa cell tumor researchers worldwide.